6.7.5 Metreleptin

Metreleptin
  • Powder for solution for injection vials 3mg, 5.8mg, 11.3mg

Notes

  1. NICE HST14: Metreleptin for treating lipodystrophy (February 2021):
    1. Metreleptin (Myalepta) is recommended, within its marketing authorisation, as an option for treating the complications of leptin deficiency in lipodystrophy for people who are 2 years and over and have generalised lipodystrophy
    1. Metreleptin (Myalepta) is recommended as an option for treating the complications of leptin deficiency in lipodystrophy for people who are 12 years and over, have partial lipodystrophy, and do not have adequate metabolic control despite having standard treatments. It is only recommended if they have an HbA1c level above 7.5%, or fasting triglycerides above 5.0mmol/litre, or both
Last updated: 06-05-2021

 

Home > Formulary > Chapters > 6. Endocrine > 6.7 Other endocrine drugs > 6.7.5 Metreleptin

 

  • First line
  • Second line
  • Specialist
  • Hospital